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Abstract 
BACKGROUND: Vitiligo is an acquired pigmentary disease, that causes progressive loss of melanocytes, 
resulting in hypopigmented skin patches. Current treatments aim at stopping the disease progression and 
achieving repigmentation of the amelanotic areas. Corticosteroids, surgery, topical immunomodulators, total 
depigmentation of normal pigmented skin and phototherapy are current treatment options for vitiligo although 
phototherapy remains the treatment of choice. There is no documented evidence that herbal bio-active products 
may also be effective treatment options for vitiligo.  
AIM: This study aimed to investigate the efficacy and safety of Vitilinex® (herbal bio- actives) alone and in 
combination with UVB narrowband (311 nm) phototherapy, in the treatment of localised stable or active forms of 
vitiligo.  
MATERIAL AND METHODS: Sixty two subjects with mean age 34.5 years (range: 18-58 years) with mild to 
moderate vitiligo, consisting of 36 females and 26 males were randomly divided into three treatment groups – 
Group A (13 females, 10 males ) treated with Vitilinex® alone; Group B (12 females, 11 males) were treated with 
Vitilinex® in combination with narrowband UVB (311 nm) phototherapy for 15 seconds, using a handheld lamp 
and Group C (8 females, 8 males ) were treated with nbUVB (311 nm) phototherapy alone, for 15 seconds over a 
12-week period.  
RESULTS: In Group A, 9 patients (39%) achieved outstanding improvement with a re-pigmentation rate higher 
than 75%, with 2 patients experiencing total repigmentation. 6 patients (26%) had marked improvement with a 
repigmentation rate between 50-75% while 5 patients (22%) showed a moderate response between 25-50% re-
pigmentation rate. 3 patients (13%) had minimal or no improvement. In Group B, 16 patients (69.5%) achieved 
outstanding improvement with a re-pigmentation rate higher than 75%, with 12 patients experiencing total re-
pigmentation. 4 patients (17.5 %) achieved a marked improvement with a re-pigmentation rate between 50-75%; 
2 patients (8.7%) showed a moderate response with a re-pigmentation rate between 25-50%. 1 (4.3%) patient 
had minimal or no improvement. In Group C, 6 patients (37.5%) achieved a re-pigmentation rate higher than 75%, 
with 2 patients experiencing total re-pigmentation. 4 patients (25%) achieved marked improvement with a re-
pigmentation rate between 50-75% while 3 patients (18.75%) had a re-pigmentation rate between 25-50%. 3 
patients (18.75%) had minimal or no improvement. 
CONCLUSION: Vitilinex® herbal bio-actives in combination with nbUVB is a more effective treatment option for 
vitiligo with 87% of the patients achieving a re-pigmentation rate higher than 50%, compared to Vitilinex® alone 
(65%) or nbUVB alone (62.5%). 
 
 
 
Introduction 
 
Vitiligo is an acquired idiopathic of unknown 
origin and is a common de-pigmentation disorder, that 
causes progressive loss of melanocytes, resulting in 
hypopigmented skin patches, hair and mucosa.  
Vitiligo is the most common disorder of 
pigmentation, affecting between 0.5-2% of the world’s 
population, and the prevalence appears to be equal 
between men and women. Although neither life-
threatening nor symptomatic, the effect of vitiligo can 
be cosmetically and psychologically devastating, 
resulting in low self-esteem, poor body image and 
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other negative quality of effects [1]. 
The exact pathogenesis of vitiligo is still to be 
elucidated [2]. Multiple mechanisms, including 
metabolic abnormalities, oxidative stress, generation 
of inflammatory mediators, cell detachment and 
autoimmune responses, are contributing factors in the 
pathogenesis [3], [4]. Vitiligo may appear at any age 
and affect both sexes equally [1], [5]. 
The clinical diagnostic features of the vitiligo 
are discolouration of the skin, characterised by well-
circumscribed, ivory or chalky white macules [6]. 
These hypopigmented macules or patches occur on 
the skin in different parts of the body including the 
face, genitalia, areolae and areas subjected to 
repeated trauma like elbows and knees. Involvement 
of mucous membranes and hair shaft is also possible 
[7] 
The current vitiligo treatments aim at stopping 
the disease progression and achieving repigmentation 
of the amelanotic areas, thus restoring the loss of 
melanocytes in the lesions. Corticosteroids, surgery, 
topical immunomodulators, total depigmentation of 
normally pigmented skin, lasers and phototherapy are 
current treatment options for vitiligo although 
phototherapy remains the treatment of choice [8], [9], 
[10]. However, many patients are now investigating 
other treatment options including herbal bio-active 
products [11]. 
This study aimed to investigate the efficacy 
and safety of Vitilinex – herbal bio-active products 
alone; Vitilinex in combination with UVB narrowband 
(311 nm) phototherapy; phototherapy alone, in the 
treatment of localised stable or active forms of vitiligo.  
 
 
Material and Methods 
 
This multi-centred observational retrospective 
study was conducted in Italy, India, Vietnam, 
Germany and Australia. Sixty-three (63) patients (30 
males, 33 females), aged from 18 to 58 years with a 
mean 34.5 years, suffering from stable or active 
vitiligo were evaluated over 12 weeks. They had not 
received any treatment for the cutaneous disease for 
at least two years. The results were subjected to 
statistical analysis.  
The patients were randomly assigned to the 
following groups: 
1) Group A- (18 females, 17 males)- 
Vitilinex® herbal bio-actives alone 
2) Group B- (15 females, 9 males) – 
Vitilinex® in combination with nb-UVB 311 nm 
phototherapy 
3) Group C- (8 males, 8 females) – nb-
UVB 311nm phototherapy alone. 
Vitilinex® consists of two products: Skin Prep 
lotion (containing-Centipeda cunninghamii, aloe vera, 
terpinol-4-ol and dihydro avenanthramide – D) and 
Emmolient (containing- black cumin seed oil, black 
pepper coleus forskohlii, Psoralea coryfolia, thyme oil, 
myrrh and neroli extracts. These oil extracts have 
shown to have very strong anti-oxidant properties.  
The Skin Prep lotion was applied to the 
affected areas and allowed to dry, followed by the 
application of the emollient. The area was then 
irradiated weekly week over 12 weeks at 311 nm, with 
a starting dose of 20% less than the minimal erythema 
dose (MED) for each patient, evaluated on a 
vitiliginous lesion 7 days before the start of treatment. 
The irradiation dose was progressively increased by 
20%. In cases where erythema was noted, we 
reduced the dose by 20% in the following treatment. 
The assessment was based on assigning a 
0% score for each lesion before therapy and 
improvement based on a percentage value to 
represent the level of repigmentation. Digital photos 
were taken at week 0 and each follow-up session. 
 
 
Results 
 
In Group A, with Vitilinex® treatment alone, 9 
patients (39%) achieved outstanding improvement 
with a re-pigmentation rate higher than 75%, with 2 
patients experiencing total repigmentation. 6 patients 
(26%) had a marked improvement with a 
repigmentation rate between 50-75% while 5 patients 
(22%) showed a moderate response between 25-50% 
re-pigmentation rate. 3 patients (13%) had minimal or 
no improvement. In Group B, with Vitilinex® in 
combination with nb-UVB 311 nm, 16 patients (69.5%) 
achieved outstanding improvement with a re-
pigmentation rate higher than 75%, with 12 patients 
experiencing total re-pigmentation. Four patients (17.5 
%) achieved a marked improvement with a re-
pigmentation rate between 50-75%; 2 patients (8.7%) 
showed a moderate response with a re-pigmentation 
rate between 25-50%. 1 (4.3%) patient had minimal or 
no improvement. We noted that when we increased 
the irradiation dose by 20%, erythema developed. We, 
therefore, kept the treatment does the same as the 
starting dose throughout the treatment, hence 
minimising the UVB exposure. As the emollient 
contains a mixture of oils, the development of 
erythema may be attributed to a burning effect with 
increased oil temperature during irradiation. 
While in Group C, phototherapy alone, 6 
patients (37.5%) achieved a re-pigmentation rate 
higher than 75%, with 2 patients experiencing total re-
pigmentation. 4 patients (25%) achieved marked 
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improvement with a re-pigmentation rate between 50-
75% while 3 patients (18.75%) had a re-pigmentation 
rate between 25-50%. 3 patients (18.75%) had 
minimal or no improvement. 
 
Figure 1: A) Before Treatment – Week 0; B) - After Combination 
Treatment– Week 12 
 
There were no adverse effects reported or 
observed following adjustment of the treatment dose 
in the combination therapy before and after treatment 
photographs are shown in Figures 1, 2, 3, and 4. 
 
 
Figure 2: A) Before Treatment – Week 0; B) After Combination 
Treatment–Week 12 
 
 
 
Discussion 
 
We evaluated the efficacy of Vitilinex® alone 
and in combination with nb-UVB 311 nm 
phototherapy, in the treatment of 63 patients with 
stable or active forms of vitiligo. The results clearly 
show that Vitilinex® in combination with phototherapy 
is significantly more effective than Vitilinex or 
phototherapy alone. In the combination therapy, 87% 
of the patients had repigmentation rate higher than 
50%, compared to Vitilinex® (65%) and phototherapy 
alone (62.5%). The irradiation dose for the 
combination therapy was kept at the minimal starting 
dose. This is also of great benefit, as it minimises the 
UV radiation exposure, which has been linked to 
intracellular mutations, which may, in turn, induce 
malignant transformation.  
 Centipeda cunninghamii in the Prep Lotion, 
contains caffeic acid and sesquiterpene lactones, 
having strong anti-inflammatory and antioxidant 
activity [12]. Terpinol-4-on, a potent constituent of tea 
tree oil, possesses antioxidant and anti-inflammatory 
properties by suppressing superoxide production and 
pro-inflammatory cytokines – TNF-alpha, IL­1beta, 
IL­8, IL­10 and PGE2 [13]. 
The antioxidant benefit of aloe vera is well 
documented and believed to impart its benefit in 
vitiligo treatment by inhibiting COX2 and PGE2 [14] 
whilst dihydro avenanthramide – D, has been shown 
to prevent UV-irradiated generation of reactive oxygen 
species and expression of matrix metalloproteinase-1 
and -3 in human dermal fibroblasts at 5 ppm [15]. 
Black cumin seed oil (Nigella sativa), used in 
the embodiment, contains thymoquinone which has 
been shown to induce melanin production and 
dispersion [16]. Piperine, from Piper nigrum, and its 
synthetic analogues, have been shown to stimulate 
mouse and human melanocyte proliferation [17], [18], 
[19]. Thyme oil, myrrh and neroli extracts have shown 
to have very strong anti-oxidant properties in cell 
culture studies [20]. 
The repigmentation in vitiligo is believed to be 
linked to a synergistic effect of all the antioxidant 
action of these herbal bio-actives. The availability of 
any new treatment that can reduce the use of UVB 
from high to low, and still be efficacious, is of 
immense benefit to both patients and treating 
physicians [21], [22], [23], [24], [25], [26], [27], [28], 
[29].  
In this study, we confirmed the efficacy of nb-
UVB in the treatment of vitiligo. However, the 
combination therapy with Vitilinex® herbal bio-actives 
proved more effective, using a lower than normal 
irradiation dose, thus reducing the potential for serious 
DNA intracellular mutations. The results also confirm 
that Vitilinex® bio-actives are effective alone. 
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